SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
3rd Apr 20079:41 amPRNDirector/PDMR Shareholding
30th Mar 20077:10 amPRNNotice of EGM
30th Mar 20077:00 amPRNPreliminary Final Results
16th Mar 20077:00 amPRNResearch Update
28th Feb 20074:23 pmPRNHolding(s) in Company
22nd Feb 20071:01 pmPRNHolding(s) in Company
21st Feb 20077:30 amPRNHolding(s) in Company
21st Feb 20077:00 amPRNResearch Update
9th Feb 200711:13 amPRNHolding(s) in Company
5th Feb 20077:00 amPRNResearch Update
30th Jan 20077:00 amPRNResearch Update
19th Jan 20073:05 pmPRNHolding(s) in Company
3rd Jan 20077:30 amPRNResearch Update
15th Dec 200611:10 amPRNTotal Voting Rights
11th Dec 20067:02 amRNSNobel Prize Congratulations
8th Dec 200611:40 amPRNHolding(s) in Company
6th Dec 200611:45 amPRNHolding(s) in Company
5th Dec 200611:10 amPRNHolding(s) in Company
29th Nov 20067:00 amPRNResearch Update
27th Nov 200610:56 amPRNDirector/PDMR Shareholding
23rd Nov 200610:15 amPRNIssue of Equity
4th Oct 200611:56 amPRNHolding(s) in Company
27th Sep 20063:55 pmPRNHolding(s) in Company
26th Sep 200610:00 amPRNRe Agreement
13th Sep 20068:30 amPRNResearch Update
1st Sep 200612:53 pmPRNHolding(s) in Company
24th Aug 20067:00 amPRNHolding(s) in Company
23rd Jun 20063:15 pmPRNResearch Update
23rd Jun 20067:30 amPRNFinal Results
15th Jun 200612:00 pmPRNResearch Update
6th Jun 20067:00 amPRNResearch Update
3rd May 20065:05 pmPRNIssue of Equity
24th Apr 200611:15 amPRNResearch Update
28th Mar 200612:40 pmPRNLicence agreement signed
20th Dec 200511:36 amPRNIssue of Equity
28th Sep 20056:30 amPRNInterim Results
27th Sep 200510:10 amPRNNotice of Results
21st Sep 20052:30 pmPRNIssue of Equity
1st Aug 200511:01 amPRNAdditional Listing
28th Jul 20056:31 amPRNHoldings in Company, Change of Broker
28th Jul 20056:30 amPRNResult of Equity Issue
12th Jul 20053:06 pmPRNHolding(s) in Company
11th Jul 200512:12 pmPRNResult of EGM
30th Jun 20059:43 amPRNAGM Statement
24th Jun 20054:41 pmRNSSchedule 1 - SR Pharma PLC
24th Jun 20052:30 pmRNSRestoration - SR Pharma PLC
24th Jun 20051:30 pmPRNPublication of Circular to Shareholders
21st Jun 20057:45 amRNSSuspension - SR Pharma PLC
21st Jun 20056:45 amPRNAcquisition(s)
9th Jun 20054:45 pmPRNNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.